The promoter activity of human Mfn2 depends on Sp1 in vascular smooth muscle cells

dc.contributor.authorSorianello, Eleonora
dc.contributor.authorZaragoza, Francesc X. (Francesc Xavier)
dc.contributor.authorFernández Pascual, Sergio
dc.contributor.authorSancho Medina, Ana
dc.contributor.authorNaón Elbirt, Déborah P.
dc.contributor.authorVila Caballer, Marian
dc.contributor.authorGonzález Navarro, Herminia
dc.contributor.authorPortugal, José, 1954-
dc.contributor.authorAndrés García, Vicente
dc.contributor.authorPalacín Prieto, Manuel
dc.contributor.authorZorzano Olarte, Antonio
dc.date.accessioned2014-12-16T13:40:05Z
dc.date.available2014-12-16T13:40:05Z
dc.date.issued2012-04-01
dc.date.updated2014-12-16T13:40:05Z
dc.description.abstractAIMS: Mitofusin-2 (Mfn2) expression is dysregulated in vascular proliferative disorders and its overexpression attenuates the proliferation of vascular smooth muscle cells (VSMCs) and neointimal lesion development after balloon angioplasty. We sought to gain insight into the mechanisms that control Mfn2 expression in VSMCs. METHODS AND RESULTS: We cloned and characterized 2 kb of the 5'-flanking region of the human Mfn2 gene. Its TATA-less promoter contains a CpG island. In keeping with this, 5'-rapid amplification of cDNA ends revealed six transcriptional start sites (TSSs), of which TSS2 and TSS5 were the most frequently used. The strong CpG island was found to be non-methylated under conditions characterized by large differences in Mfn2 gene expression. The proximal Mfn2 promoter contains six putative Sp1 motifs. Sp1 binds to the Mfn2 promoter and its overexpression activates the Mfn2 promoter in VSMCs. Chemical inhibition of Sp1 reduced Mfn2 expression, and Sp1 silencing reduced transcriptional activity of the Mfn2 promoter. In keeping with this view, Sp1 and Mfn2 mRNA levels were down-regulated in the aorta early after an atherogenic diet in apolipoprotein E-knockout mice or in VSMCs cultured in the presence of low serum. CONCLUSION: Sp1 is a key factor in maintaining basal Mfn2 transcription in VSMCs. Given the anti-proliferative actions of Mfn2, Sp1-induced Mfn2 transcription may represent a mechanism for prevention of VSMC proliferation and neointimal lesion and development.
dc.format.extent47 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec618477
dc.identifier.issn0008-6363
dc.identifier.urihttps://hdl.handle.net/2445/60798
dc.language.isoeng
dc.publisherOxford University Press
dc.relation.isformatofVersió postprint del document publicat a: http://dx.doi.org/10.1093/cvr/cvs006
dc.relation.ispartofCardiovascular Research, 2012, vol. 94, num. 1, p. 38-47
dc.relation.urihttp://dx.doi.org/10.1093/cvr/cvs006
dc.rights(c) European Society of Cardiology, 2012
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Biologia Cel·lular, Fisiologia i Immunologia)
dc.subject.classificationMetabolisme cel·lular
dc.subject.classificationTranscripció genètica
dc.subject.classificationProteïnes
dc.subject.classificationMalalties cardiovasculars
dc.subject.otherCell metabolism
dc.subject.otherGenetic transcription
dc.subject.otherProteins
dc.subject.otherCardiovascular diseases
dc.titleThe promoter activity of human Mfn2 depends on Sp1 in vascular smooth muscle cells
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
618477.pdf
Mida:
2.79 MB
Format:
Adobe Portable Document Format